Literature DB >> 18154423

Obturator bypass as an alternative technique for revascularization in patients with infected femoral pseudoaneurysms.

Abbas Rabbani1, Majid Moini, Mohammad-Reza Rasouli.   

Abstract

BACKGROUND: Management of the infected femoral artery pseudoaneurysm has remained controversial. Although common femoral artery ligation and local debridement is an acceptable approach, some patients need revascularization for the treatment of leg ischemia or intermittent claudication. In this study, we report obturator bypass as an alternative technique that has been done at Sina Hospital, Tehran, Iran during a 10-year period.
METHODS: This was a retrospective study and the data were obtained from the patients' medical records.
RESULTS: Ten obturator bypasses were done on nine patients. Two cases had previous history of ligation of the femoral artery branches. One death and two forefoot amputations occurred.
CONCLUSION: Femoral artery ligation has been suggested as the treatment of choice for the management of infected femoral artery pseudoaneurysms. Among the extra-anatomic bypasses, the obturator bypass is an acceptable alternative with favorable results.

Entities:  

Mesh:

Year:  2008        PMID: 18154423     DOI: 08111/AIM.0012

Source DB:  PubMed          Journal:  Arch Iran Med        ISSN: 1029-2977            Impact factor:   1.354


  3 in total

1.  Diagnosis and management of mycotic aneurysms.

Authors:  Luis R León; Joseph L Mills
Journal:  Curr Infect Dis Rep       Date:  2009-07       Impact factor: 3.725

2.  Aortobifemoral Reconstruction with Right Extra-Anatomic Obturator Foramen Bypass due to a Septic Groin.

Authors:  Carlos A Hinojosa; Javier E Anaya-Ayala; Hugo Laparra-Escareno; Rene Lizola; Adriana Torres-Machorro
Journal:  Vasc Specialist Int       Date:  2016-06-30

3.  [Treatment strategies and outcomes for injection-associated inguinal perivascular abscesses in intravenous drug addicts].

Authors:  D Liebetrau; E Feder; S Zerwes; Y Goßlau; A Hyhlik-Dürr
Journal:  Chirurg       Date:  2021-11       Impact factor: 0.955

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.